Cataract News and Research

Latest Cataract News and Research

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.

28 Sep 2015

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.

24 Sep 2015

UK’s GPs, optometrists confirm link between smoking and loss of vision

Smokey eyes are regarded as sexy, sultry and stunning. But nothing could be further from the truth, according to new research unveiled this National Eye Health Week.

18 Sep 2015

IRIDEX launches novel intra-ocular pressure monitoring device

IRIDEX Corporation today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator of the tonometer.

8 Sep 2015

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

4 Sep 2015

Researchers find genetic cause of previously unknown disease

Researchers at the University of Oslo and Oslo University Hospital have found the genetic cause of a previously undescribed disease. With this, they have solved an over ten year old medical conundrum.

1 Sep 2015

Temporary postnatal visual deprivation induces permanent auditory responses in the brain's visual area

A brief period of postnatal visual deprivation, when early in life, drives a rewiring of the brain areas involved in visual processing, even if the visual restoration is completed well before the baby reaches one year of age, researchers at the University of Trento, McMaster University, and the University of Montreal revealed today in Current Biology.

21 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

Omeros plans to file patent infringement lawsuit against Par

Omeros Corporation today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

17 Aug 2015

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.

12 Aug 2015

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.

3 Aug 2015

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

23 Jul 2015

New study suggests novel ways to treat serous retinal detachment

Wet age-related macular degeneration (AMD) is the leading cause of severe vision loss in older individuals. AMD and other serious chronic eye problems that affect younger individuals result when fluid accumulates abnormally under or within the retina. A new study published in The American Journal of Pathology shows for the first time that the release of substances from mast cells may be a causal factor in this type of eye pathology, and inhibitors of this release may offer new ways to treat serous retinal detachment.

22 Jul 2015

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder.

15 Jul 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

University of Delaware researchers identify prime suspects in cataract formation

When cataracts encroach on the eyes, the only effective remedy is to surgically replace the eyes' lenses with synthetic substitutes. But what if scientists found a way to delay or prevent cataracts from forming in the first place? Researchers at the University of Delaware may have found such an opportunity by identifying the prime suspects in the formation of cataracts - deficiency of two genes that encode regulatory proteins.

19 Jun 2015

Iowa's advanced driving simulator to help assess newly developed artificial lens for cataract patients

A miniature version of the University of Iowa's advanced driving simulator will participate in a clinical trial later this year to assess a patient's driving ability after cataract surgery.

17 Jun 2015

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.

16 Jun 2015

FE65 and FE65L1 proteins may become therapeutic target for muscular dystrophy, cataracts and Alzheimer's

Amyloid precursor protein (APP), a key protein implicated in the development Alzheimer's disease, may play an important role in eye and muscle health. In a new report published in the June 2015 issue of The FASEB Journal, scientists have discovered that when proteins that bind to the APP, called FE65 and FE65L1, are deleted, they cause cataracts and muscle weakness in mice.

10 Jun 2015

Despite low value and high costs, certain preoperative tests still common in U.S.

Professional physician associations consider certain routine tests before elective surgery to be of low value and high cost, and have sought to discourage their utilization.

9 Jun 2015

Cataract News and Research

Latest Cataract News and Research

ILUVIEN continues to show positive results in Europe

Alimera Sciences announces results from ongoing study on ILUVIEN

UK’s GPs, optometrists confirm link between smoking and loss of vision

IRIDEX launches novel intra-ocular pressure monitoring device

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Researchers find genetic cause of previously unknown disease

Temporary postnatal visual deprivation induces permanent auditory responses in the brain's visual area

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros plans to file patent infringement lawsuit against Par

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

New study suggests novel ways to treat serous retinal detachment

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

University of Delaware researchers identify prime suspects in cataract formation

Iowa's advanced driving simulator to help assess newly developed artificial lens for cataract patients

Omeros signs exclusive license agreement with Fagron affiliates for commercialization of OMS103

FE65 and FE65L1 proteins may become therapeutic target for muscular dystrophy, cataracts and Alzheimer's

Despite low value and high costs, certain preoperative tests still common in U.S.

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cataract News and Research

Latest Cataract News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in